IntegraGen reports 2020 annual results: 10% growth in revenue from current operations and achievement of breakeven operating profits

Bernard Courtieu, CEO of IntegraGen said: “2020 was an exceptional year for IntegraGen in several ways. Commercial activities achieved double-digit growth, results were close to breakeven for the second consecutive year, and the company’s cash position was strengthened, despite the considerable impact of the health crisis.”

Click here to (…)  » 

IntegraGen Reports Results for 1st Half of 2020

IntegraGen has announced today its financial results for the first half of 2020 with the accounts having been reviewed by the Board of Directors on 17 September 2020.

Company posts positive operating performance (EBITDA) for the second consecutive semester, supported by revenue growth (+5%) and  confirms (…)  » 

Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN

Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN to acquire all outstanding shares at a price of 2.20€ per share. This transaction would bring together OncoDNA’s expertise in oncology precision medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of (…)  » 

IntegraGen reports 2019 annual results

integragen

+20% sales growth, positive gross operating surplus during second half of year, and close to break-even for the year

IntegraGen announced its financial results for the year ending December 31, 2019. The annual accounts were approved by the Board of Directors at a meeting held on April 2, 2020.

Operating (…)  » 

IntegraGen announces leading U.S. cancer center to use MERCURY™ cloud-based tool for oncology sequencing data interpretation and reporting

IntegraGen today announced Dana-Farber Cancer Institute will utilize the company’s MERCURY™ cloud-based software as part of their analysis and reporting process for sequencing data obtained from tumors of cancer patients. Dana-Farber plans to utilize MERCURY to assist in the analysis of sequencing data obtained from small and large (…)  »